CSLHAM:CSJ +0.07%73 EBITDA Margin % is 13.12% as of Dec. 2025, which is 60% below its 10-year median of 33.15. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €170.71 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 945 Biotechnology companies, CSL ranks better than 77.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CSL's EBITDA for the
six
months ended in Dec. 2025 was €907 Mil. CSL's Revenue for the
six
months ended in Dec. 2025 was €6,911 Mil. Therefore, CSL's EBITDA margin for the quarter that ended in Dec. 2025 was 13.12%.
CSL (HAM:CSJ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CSL EBITDA Margin % Related Terms
CSL EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CSL's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:CSJ vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, CSL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CSL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (HAM:CSJ) has a EBITDA Margin % of 13.12% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CSL and its competitors. This is 60% below median its historical median of 33.15. Over the past decade, CSL's EBITDA Margin % has ranged from 13.12 to 35.40. According to the industry distribution chart, CSL ranks #212 out of 945 companies in the Biotechnology industry, placing it in the top 22.4%.
Is CSL's EBITDA Margin % too high?
CSL's current EBITDA Margin % of 13.12% is 60% below median its 10-year median of 33.15. Over the past 10 years, this metric has ranged from a low of 13.12 to a high of 35.40. Based on the distribution chart, CSL ranks #212 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #212 out of 945 companies for EBITDA Margin %. This places CSL in the top 22% of its industry — outperforming the majority of peers. Historically, CSL's own EBITDA Margin % has ranged from 13.12 to 35.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CSL and its competitors. CSL's current EBITDA Margin % is 13.12%, which is 60% below median its own 10-year median of 33.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €68.23 — trading 60% below its estimated fair value. The current EBITDA Margin % is 13.12%, which is 60% below median its 10-year median of 33.15. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CSL (HAM:CSJ), the current EBITDA Margin % is 13.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €68.23 is trading 60% below its estimated GF Value™ of €170.71.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
EBITDA Margin %: 13.12% (60% below median its 10-year median of 33.15)
GF Value™: €170.71 vs. price of €68.23 (60% below fair value)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
